ESMO 2023 Insights: "EMBARK Secondary Endpoints - Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Ugo De Giorgi
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Ugo De Giorgi
Disclaimer: This video was recorded prior to FDA approval of enzalutamide on November 17, 2023 for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
Comments 0
Login to view comments.
Click here to Login
